We use cookies on our website to enhance your browsing experience. If you continue to use our website, we assume that you are happy for us to do this. To understand more about how we use cookies, or to change your preferences and browser settings, please see our Cookie Policy.

We use cookies on our website to enhance your browsing experience. If you continue to use our website, we assume that you are happy for us to do this. To understand more about how we use cookies, or to change your preferences and browser settings, please see our Cookie Policy.

Davis Polk

Title

Addressing the Growing Threat of Securities Class Actions in the Life Sciences Sector

Client Memorandum

Created date

12/6/2016

Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a developing device or drug, the company’s stock price drops and plaintiffs’ lawyers pounce. They claim that the company’s prior statements about the drug or device were too rosy. The attached memorandum addresses that all-too-typical fact pattern and describes the body of case law that has developed for assessing liability when a company has offered opinions about a new potential product.